Real-world data from a single Greek centre on the use of secukinumab in plaque psoriasis: effectiveness, safety, drug survival, and identification of patients that sustain optimal response.
Natalia RompotiPolytimi SidiropoulouP PanagakisA StratigosM PapoutsakiE StefanakiC VavouliM PolitouA BefonP KostakisD RigopoulosE NicolaidouPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2020)
Secukinumab showed consistently high effectiveness in this real-life cohort, with an acceptable safety profile. Over time, persistence of PASI ≤3 response appears to be lower in patients with high BMI or multiple comorbidities.
Keyphrases
- randomized controlled trial
- end stage renal disease
- ankylosing spondylitis
- systematic review
- ejection fraction
- newly diagnosed
- coronary artery disease
- peritoneal dialysis
- prognostic factors
- emergency department
- big data
- electronic health record
- rheumatoid arthritis
- weight gain
- free survival
- artificial intelligence
- weight loss